
AbCellera Biologics Inc.
NASDAQ:ABCL
2.35 (USD) • At close March 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|---|---|
Revenue
| 28.833 | 38.025 | 485.424 | 375.203 | 233.155 | 11.612 | 8.831 |
Cost of Revenue
| 0 | 0 | 66.436 | 45.516 | 27.143 | 10.113 | 5.803 |
Gross Profit
| 28.833 | 38.025 | 418.988 | 329.687 | 206.012 | 1.499 | 3.028 |
Gross Profit Ratio
| 1 | 1 | 0.863 | 0.879 | 0.884 | 0.129 | 0.343 |
Reseach & Development Expenses
| 167.259 | 175.658 | 107.879 | 62.062 | 29.393 | 10.113 | 5.803 |
General & Administrative Expenses
| 72.711 | 60.999 | 55.485 | 41.848 | 11.91 | 2.749 | 2.151 |
Selling & Marketing Expenses
| 12.779 | 14.18 | 11.27 | 6.913 | 3.842 | 1.263 | 0.712 |
SG&A
| 85.49 | 75.179 | 66.755 | 48.761 | 15.752 | 4.012 | 2.863 |
Other Expenses
| 90.85 | 24.395 | 17.289 | -3.035 | -3.484 | -0.17 | -0.676 |
Operating Expenses
| 343.599 | 275.232 | 191.923 | 107.788 | 41.661 | 13.954 | 7.99 |
Operating Income
| -314.766 | -237.207 | 216.511 | 204.413 | 156.031 | -4.117 | -0.753 |
Operating Income Ratio
| -10.917 | -6.238 | 0.446 | 0.545 | 0.669 | -0.355 | -0.085 |
Total Other Income Expenses Net
| 114.371 | 63.178 | 22.588 | 14.736 | 1.802 | 1.906 | 1.062 |
Income Before Tax
| -200.395 | -174.029 | 239.099 | 219.149 | 157.833 | -2.211 | 0.309 |
Income Before Tax Ratio
| -6.95 | -4.577 | 0.493 | 0.584 | 0.677 | -0.19 | 0.035 |
Income Tax Expense
| -37.538 | -27.631 | 80.58 | 65.685 | 38.915 | 0.209 | 1.274 |
Net Income
| -162.857 | -146.398 | 158.519 | 153.464 | 118.918 | -2.42 | 0.309 |
Net Income Ratio
| -5.648 | -3.85 | 0.327 | 0.409 | 0.51 | -0.208 | 0.035 |
EPS
| -0.55 | -0.51 | 0.56 | 0.56 | 0.44 | -0.016 | 0.001 |
EPS Diluted
| -0.55 | -0.51 | 0.5 | 0.48 | 0.44 | -0.016 | 0.001 |
EBITDA
| -204.148 | -192.158 | 272.201 | 241.624 | 169.615 | -0.397 | 0.165 |
EBITDA Ratio
| -7.08 | -5.053 | 0.569 | 0.646 | 0.729 | -0.029 | 0.204 |